Compliance Rate
Compliance Rate
50.0%
Compliant submissions
1
Incompliant submissions
1
Total trials
2
My Organizations' Clinical Trials
Showing 1000 of 3499 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/06
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/31/99
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/31/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/07/20
End: 07/30/26
Due: 07/30/27
Phase: N/A
Priority: Normal
Start: 09/06/18
End: 03/23/28
Due: 03/23/29
Phase: N/A
Priority: Normal
Start: 06/30/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/09/06
End: 01/20/10
Due: 01/20/11
Phase: N/A
Priority: Normal
Start: 10/31/95
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 02/11/14
End: 05/10/19
Due: 05/10/20
Phase: N/A
Priority: Normal
Start: 12/31/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/06/11
End: 04/24/13
Due: 04/24/14
Phase: N/A
Priority: Normal
Start: 07/31/04
End: 01/31/11
Due: 01/31/12
Phase: N/A
Priority: Normal
Start: 08/31/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/26/20
End: 09/16/21
Due: 09/16/22
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
Phase: N/A
Priority: Normal
Start: 09/14/07
End: 03/21/17
Due: 03/21/18
Phase: N/A
Priority: Normal
Start: 04/07/00
End: 03/26/20
Due: 03/26/21
Phase: N/A
Priority: Normal
Start: 02/25/09
End: 12/22/21
Due: 12/22/22
Phase: N/A
Priority: Normal
Start: 09/22/23
End: 08/31/25
Due: 08/31/26
Phase: N/A
Priority: Normal
Start: 04/07/23
End: 08/31/26
Due: 08/31/27
Phase: N/A
Priority: Normal
Start: 03/01/11
End: 06/01/26
Due: 06/01/27
Phase: N/A
Priority: Normal
Start: 08/11/17
End: 06/07/25
Due: 06/07/26
Phase: N/A
Priority: Normal
Start: 07/27/05
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 04/24/24
End: 06/01/27
Due: 06/01/28
Phase: N/A
Priority: Normal
Start: 07/30/12
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 11/10/15
End: 01/01/28
Due: 01/01/29